Drug Trial Radar · NCT04255433
A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
Last checked: Nov 19, 2026Latest source record: Jul 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
13,299
Actual
Start
May 29, 2020
Primary completion
Jun 12, 2025
Study completion Jun 12, 2025
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- First posted
- Feb 5, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the trial is to assess the efficacy and safety of tirzepatide to dulaglutide in participants with type 2 diabetes and increased cardiovascular risk.
Conditions
- Type 2 Diabetes Mellitus
Interventions
TirzepatideDrug
Administered SC
DulaglutideDrug
Administered SC
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants From Randomization to First Occurrence of Death From MACE-3 [Composite Endpoint of Major Adverse Cardiovascular Events Death From Cardiovascular Causes, Myocardial Infarction (MI) or Stroke]Time frame: From randomization (week 0) up to week 259
Locations
635 sites in 31 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham Medical Center
Birmingham, Alabama
John Muir Medical Center - Concord Campus
Concord, California
Valley Clinical Trials, Inc.
Covina, California
AMCR Institute
Escondido, California
Valley Research
Fresno, California
NorCal Medical Research, Inc
Greenbrae, California
UCSD - Altman Clinical and Translational Research Institute (ACTRI)
La Jolla, California
First Valley Medical Group
Lancaster, California
Monterey Endocrine & Diabetes Institute, Inc.
Monterey, California
Riverside University Health System - Medical Center
Moreno Valley, California
Diabetes Associates Medical Group
Orange, California
Pasadena Clinical Research
Pasadena, California
LCGK Research
San Carlos, California
Norcal Endocrinology & Internal Medicine
San Ramon, California
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Torrance, California
University of Colorado Anschutz Medical Campus
Aurora, Colorado
CMR of Greater New Haven, LLC
Hamden, Connecticut
Chase Medical Research, LLC
Waterbury, Connecticut
Orlando Heart & Vascular Institute, LLC
Altamonte Springs, Florida
Excel Medical Clinical Trials
Boca Raton, Florida
Encore Medical Research
Hollywood, Florida
East Coast Institute for Research, LLC
Jacksonville, Florida
Jacksonville Center for Clinical Research
Jacksonville, Florida
Accel Research Sites - St. Pete-Largo Clinical Research Unit
Largo, Florida
Ocala Caridovascular Research
Ocala, Florida
Cardiology Partners Clinical Research Institute - Palm Beach Gardens
Palm Beach Gardens, Florida
Peace River Cardiovascular Center
Port Charlotte, Florida
Professional Health Care of Pinellas
St. Petersburg, Florida
Cardiology Partners Clinical Research Institute - Wellington
Wellington, Florida
Clinical Research of Central Florida
Winter Haven, Florida
Atlanta Diabetes Associates
Atlanta, Georgia
Kaiser Permanente - Dutluth, GA
Duluth, Georgia
NSC Research
Johns Creek, Georgia
Physicians Research Associates
Lawrenceville, Georgia
East Coast Institute for Research at The Jones Center
Macon, Georgia
Atlanta Heart Specialists
Tucker, Georgia
East-West Medical Research Institute
Honolulu, Hawaii
VA Pacific Islands Health Care System
Honolulu, Hawaii
Elite Clinical Trials
Blackfoot, Idaho
Rocky Mountain Clinical Research
Idaho Falls, Idaho
Showing 40 of 635 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.